AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-362-6295
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5 million
Profitability
Miscellaneous
Employees78
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions
What is AnaptysBio's stock symbol?
AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."
How were AnaptysBio's earnings last quarter?
AnaptysBio Inc (NASDAQ:ANAB) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. The biotechnology company earned $5 million during the quarter. The business's revenue for the quarter was up 4900.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.57) earnings per share. View AnaptysBio's Earnings History.
When is AnaptysBio's next earnings date?
What price target have analysts set for ANAB?
8 Wall Street analysts have issued 12-month target prices for AnaptysBio's shares. Their forecasts range from $48.00 to $140.00. On average, they expect AnaptysBio's stock price to reach $102.86 in the next twelve months. This suggests a possible upside of 174.9% from the stock's current price. View Analyst Price Targets for AnaptysBio.
What is the consensus analysts' recommendation for AnaptysBio?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AnaptysBio.
Has AnaptysBio been receiving favorable news coverage?
News stories about ANAB stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AnaptysBio earned a news impact score of -2.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for AnaptysBio.
Who are some of AnaptysBio's key competitors?
Some companies that are related to AnaptysBio include Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR), FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Emergent Biosolutions (EBS), HUTCHISON CHINA/S (HCM) and Genmab A/S (GMAB).
What other stocks do shareholders of AnaptysBio own?
Who are AnaptysBio's key executives?
AnaptysBio's management team includes the folowing people:
- Mr. Hamza Suria, Pres, CEO & Director (Age 43)
- Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
- Prof. Marco Londei, Chief Medical Officer (Age 62)
- Mr. Eric J. Loumeau, Gen. Counsel (Age 56)
- Dr. Hemant Kumar, Sr. VP of Manufacturing
When did AnaptysBio IPO?
(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are AnaptysBio's major shareholders?
AnaptysBio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Whittier Trust Co. (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Marco Londei and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.
Which major investors are buying AnaptysBio stock?
How do I buy shares of AnaptysBio?
Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AnaptysBio's stock price today?
One share of ANAB stock can currently be purchased for approximately $37.42.
How big of a company is AnaptysBio?
AnaptysBio has a market capitalization of $1.01 billion and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.View Additional Information About AnaptysBio.
What is AnaptysBio's official website?
How can I contact AnaptysBio?
AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]
MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
